Solbec progresses psoriasis trial
Tuesday, 05 October, 2004
Solbec Pharmaceuticals (ASX:SBP) has completed the first stage of its Phase I clinical trial for a psoriasis treatment based on its lead drug candidate SBP002.
The drug, formulated as a cream, was tested on a number of healthy individuals with no unwanted effects or reactions recorded. The company will now move on to test the treatment at a therapeutic dose, in preparation for larger Phase II trials, expected to commence after the Phase I trial winds up in early 2005.
The clinical trials are being conducted by clinical trials unit CMAX, part of listed Australian company IDT, in Adelaide.
SBP002 is also under investigation by Solbec as a cancer treatment for mesothelioma and melanoma.
New molecular mechanism found for depression
Depression may not only result from simple neuronal damage but can also arise from the...
Over-the-counter medications linked to antibiotic resistance
Over-the-counter medications such as ibuprofen and paracetamol are quietly driving antibiotic...
Subtle heart dysfunction detected in young adults with bipolar
A new study reveals that myocardial dysfunction is already evident in patients with bipolar...
